Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,220
archived clinical trials in
HIV / AIDS

A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Minneapolis, MN
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Omaha, NE
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Omaha, NE
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Las Vegas, NV
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Newark, NJ
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Newark, NJ
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Bronx, NY
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Bronx, NY
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
New York, NY
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Valhalla, NY
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Valhalla, NY
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Chapel Hill, NC
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Charlotte, NC
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Durham, NC
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Durham, NC
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Cincinnati, OH
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Portland, OR
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Philadelphia, PA
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Providence, RI
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Providence, RI
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Charleston, SC
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Charleston, SC
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Dallas, TX
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Fort Worth, TX
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Fort Worth, TX
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Houston, TX
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Houston, TX
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Longview, TX
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Longview, TX
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Salt Lake City, UT
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated:  3/8/2018
GSK Investigational Site
mi
from
Darlinghurst, Sydney,
A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial)
A Randomized, Double-Blind Study of the Safety and Efficacy of GSK1349572 Plus Abacavir/Lamivudine Fixed-Dose Combination Therapy Administered Once Daily Compared to Atripla Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects
Status: Enrolling
Updated: 3/8/2018
GSK Investigational Site
mi
from
Darlinghurst, Sydney,
Click here to add this to my saved trials
Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX®-GP (Gag, Pol, Env) DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adult Participants
Status: Enrolling
Updated:  3/12/2018
Hope Clinic of the Emory Vaccine Center CRS
mi
from
Decatur, GA
Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX®-GP (Gag, Pol, Env) DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adult Participants
Status: Enrolling
Updated: 3/12/2018
Hope Clinic of the Emory Vaccine Center CRS
mi
from
Decatur, GA
Click here to add this to my saved trials
Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX®-GP (Gag, Pol, Env) DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adult Participants
Status: Enrolling
Updated:  3/12/2018
University of Rochester Vaccines to Prevent HIV Infection CRS
mi
from
Rochester, NY
Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX®-GP (Gag, Pol, Env) DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adult Participants
Status: Enrolling
Updated: 3/12/2018
University of Rochester Vaccines to Prevent HIV Infection CRS
mi
from
Rochester, NY
Click here to add this to my saved trials
Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX®-GP (Gag, Pol, Env) DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adult Participants
Status: Enrolling
Updated:  3/12/2018
Vanderbilt Vaccine (VV) CRS
mi
from
Nashville, TN
Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX®-GP (Gag, Pol, Env) DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adult Participants
Status: Enrolling
Updated: 3/12/2018
Vanderbilt Vaccine (VV) CRS
mi
from
Nashville, TN
Click here to add this to my saved trials
Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX®-GP (Gag, Pol, Env) DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adult Participants
Status: Enrolling
Updated:  3/12/2018
Seattle Vaccine and Prevention CRS
mi
from
Seattle, WA
Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults
A Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PENNVAX®-GP (Gag, Pol, Env) DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adult Participants
Status: Enrolling
Updated: 3/12/2018
Seattle Vaccine and Prevention CRS
mi
from
Seattle, WA
Click here to add this to my saved trials
Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women
Phase 1 Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women
Status: Enrolling
Updated:  3/12/2018
Alabama CRS
mi
from
Birmingham, AL
Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women
Phase 1 Pharmacokinetic Study of the Dapivirine Vaginal Ring in Lactating Women
Status: Enrolling
Updated: 3/12/2018
Alabama CRS
mi
from
Birmingham, AL
Click here to add this to my saved trials
An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study
An Expanded Compassionate Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PRO140_CD02 Study
Status: Enrolling
Updated:  3/12/2018
CD02 EA Investigational site
mi
from
Orlando, FL
An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study
An Expanded Compassionate Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PRO140_CD02 Study
Status: Enrolling
Updated: 3/12/2018
CD02 EA Investigational site
mi
from
Orlando, FL
Click here to add this to my saved trials
Phase 2a Study of Dapivirine Ring in Adolescent Females
Phae 2A Study of a Vaginal Ring Containing Dapivirine in Adolescent Females
Status: Enrolling
Updated:  3/15/2018
Alabama CRS, 84519th Street South, BBRB 203A
mi
from
Birmingham, AL
Phase 2a Study of Dapivirine Ring in Adolescent Females
Phae 2A Study of a Vaginal Ring Containing Dapivirine in Adolescent Females
Status: Enrolling
Updated: 3/15/2018
Alabama CRS, 84519th Street South, BBRB 203A
mi
from
Birmingham, AL
Click here to add this to my saved trials
Phase 2a Study of Dapivirine Ring in Adolescent Females
Phae 2A Study of a Vaginal Ring Containing Dapivirine in Adolescent Females
Status: Enrolling
Updated:  3/15/2018
The university of Colorado, 13123 E. 16th Ave., Box 025
mi
from
Aurora, CO
Phase 2a Study of Dapivirine Ring in Adolescent Females
Phae 2A Study of a Vaginal Ring Containing Dapivirine in Adolescent Females
Status: Enrolling
Updated: 3/15/2018
The university of Colorado, 13123 E. 16th Ave., Box 025
mi
from
Aurora, CO
Click here to add this to my saved trials
Phase 2a Study of Dapivirine Ring in Adolescent Females
Phae 2A Study of a Vaginal Ring Containing Dapivirine in Adolescent Females
Status: Enrolling
Updated:  3/15/2018
The Fenway Institute, 1340 Boylston Street
mi
from
Boston, MA
Phase 2a Study of Dapivirine Ring in Adolescent Females
Phae 2A Study of a Vaginal Ring Containing Dapivirine in Adolescent Females
Status: Enrolling
Updated: 3/15/2018
The Fenway Institute, 1340 Boylston Street
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 2a Study of Dapivirine Ring in Adolescent Females
Phae 2A Study of a Vaginal Ring Containing Dapivirine in Adolescent Females
Status: Enrolling
Updated:  3/15/2018
Montefiore Medical Center, 3514 Wayne Ave
mi
from
Bronx, NY
Phase 2a Study of Dapivirine Ring in Adolescent Females
Phae 2A Study of a Vaginal Ring Containing Dapivirine in Adolescent Females
Status: Enrolling
Updated: 3/15/2018
Montefiore Medical Center, 3514 Wayne Ave
mi
from
Bronx, NY
Click here to add this to my saved trials
Phase 2a Study of Dapivirine Ring in Adolescent Females
Phae 2A Study of a Vaginal Ring Containing Dapivirine in Adolescent Females
Status: Enrolling
Updated:  3/15/2018
University of Pittsburgh CRS, 3601 fifth Ave, Room 737
mi
from
Pittsburgh, PA
Phase 2a Study of Dapivirine Ring in Adolescent Females
Phae 2A Study of a Vaginal Ring Containing Dapivirine in Adolescent Females
Status: Enrolling
Updated: 3/15/2018
University of Pittsburgh CRS, 3601 fifth Ave, Room 737
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Phase 2a Study of Dapivirine Ring in Adolescent Females
Phae 2A Study of a Vaginal Ring Containing Dapivirine in Adolescent Females
Status: Enrolling
Updated:  3/15/2018
University of Pittsburgh CRS, 3601 Fifth Avenue, Room 737; Falk Medical Building
mi
from
Pittsburgh, PA
Phase 2a Study of Dapivirine Ring in Adolescent Females
Phae 2A Study of a Vaginal Ring Containing Dapivirine in Adolescent Females
Status: Enrolling
Updated: 3/15/2018
University of Pittsburgh CRS, 3601 Fifth Avenue, Room 737; Falk Medical Building
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Phase 2a Study of Dapivirine Ring in Adolescent Females
Phae 2A Study of a Vaginal Ring Containing Dapivirine in Adolescent Females
Status: Enrolling
Updated:  3/15/2018
St. Jude Children's Research Hospital 262 Danny Thomas PL.
mi
from
Memphis, TN
Phase 2a Study of Dapivirine Ring in Adolescent Females
Phae 2A Study of a Vaginal Ring Containing Dapivirine in Adolescent Females
Status: Enrolling
Updated: 3/15/2018
St. Jude Children's Research Hospital 262 Danny Thomas PL.
mi
from
Memphis, TN
Click here to add this to my saved trials
Depression and ART Adherence in HIV+ Latinos
Addressing Depression and ART Adherence in HIV+ Latinos on the U.S.-Mexico Border
Status: Enrolling
Updated:  3/15/2018
Centro de Salud Familiar La Fe CARE Center
mi
from
El Paso, TX
Depression and ART Adherence in HIV+ Latinos
Addressing Depression and ART Adherence in HIV+ Latinos on the U.S.-Mexico Border
Status: Enrolling
Updated: 3/15/2018
Centro de Salud Familiar La Fe CARE Center
mi
from
El Paso, TX
Click here to add this to my saved trials
Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases
Phase I/II Study of Reduced Intensity Conditioning for Patients With Non-Malignant Diseases Using CD3+/CD19+ Depleted Unrelated Donor or Partially Matched Related Donor Peripheral Stem Cells
Status: Enrolling
Updated:  3/16/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases
Phase I/II Study of Reduced Intensity Conditioning for Patients With Non-Malignant Diseases Using CD3+/CD19+ Depleted Unrelated Donor or Partially Matched Related Donor Peripheral Stem Cells
Status: Enrolling
Updated: 3/16/2018
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated:  3/22/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated: 3/22/2018
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated:  3/22/2018
Clinical Research Facility
mi
from
Washington,
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated: 3/22/2018
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated:  3/22/2018
Clinical Research Facility
mi
from
Orlando, FL
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated: 3/22/2018
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated:  3/22/2018
Clinical Research Facility
mi
from
Vero Beach, FL
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated: 3/22/2018
Clinical Research Facility
mi
from
Vero Beach, FL
Click here to add this to my saved trials
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated:  3/22/2018
Clinical Research Facility
mi
from
Boston, MA
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated: 3/22/2018
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated:  3/22/2018
Clinical Research Facility
mi
from
Annandale, VA
Safety/Effectiveness of Oral Chemokine Coreceptor 5 (CCR5) Antagonist INCB009471 in R5-tropic HIV Infected Patients
A Randomized, Double-blind, Placebo-controlled Study Exploring the Safety, Tolerability, PK & Virological Effect of Once Daily Oral Dosing of INCB009471 as Monotherapy for 14 Days in ARV-naïve/Limited ARV-experienced, HIV-1 Infected Pts.
Status: Enrolling
Updated: 3/22/2018
Clinical Research Facility
mi
from
Annandale, VA
Click here to add this to my saved trials
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Status: Enrolling
Updated:  3/23/2018
Hennepin County Medical Center
mi
from
Minneapolis, MN
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Status: Enrolling
Updated: 3/23/2018
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Status: Enrolling
Updated:  3/23/2018
Hennepin County Medical Center
mi
from
Minneapolis, MN
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease
Status: Enrolling
Updated: 3/23/2018
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Technology-Delivered Peer-to-Peer Support ART Adherence Intervention for Substance-using HIV+ Adults
A Technology-Delivered Peer-to-Peer Support ART Adherence Intervention for Substance-using HIV+ Adults
Status: Enrolling
Updated:  3/23/2018
Center for HIV Education Studies and Training, Hunter College
mi
from
New York, NY
A Technology-Delivered Peer-to-Peer Support ART Adherence Intervention for Substance-using HIV+ Adults
A Technology-Delivered Peer-to-Peer Support ART Adherence Intervention for Substance-using HIV+ Adults
Status: Enrolling
Updated: 3/23/2018
Center for HIV Education Studies and Training, Hunter College
mi
from
New York, NY
Click here to add this to my saved trials
PLUS PINK: HHRP+ Adaptation for Women With HIV Under Community Supervision
PLUS PINK: HHRP+ Adaptation for Women With HIV Under Community Supervision
Status: Enrolling
Updated:  3/23/2018
Yale AIDS Program
mi
from
New Haven, CT
PLUS PINK: HHRP+ Adaptation for Women With HIV Under Community Supervision
PLUS PINK: HHRP+ Adaptation for Women With HIV Under Community Supervision
Status: Enrolling
Updated: 3/23/2018
Yale AIDS Program
mi
from
New Haven, CT
Click here to add this to my saved trials
A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA
A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA
Status: Enrolling
Updated:  3/26/2018
Gilead Sciences, Inc.
mi
from
Foster City, CA
A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA
A Prospective, Observational, Drug Utilization Study of Subjects Taking Truvada for Pre-exposure Prophylaxis in the USA
Status: Enrolling
Updated: 3/26/2018
Gilead Sciences, Inc.
mi
from
Foster City, CA
Click here to add this to my saved trials
Functionality of Male Condoms With a Silicone Elastomer Vaginal RIng
A Multicenter, Open-Label, Randomized, Two-Period, Crossover Non-inferiority Trial to Assess the Functionality of Male Condoms With a Silicone Elastomer Vaginal Ring
Status: Enrolling
Updated:  3/27/2018
California Family Health Council
mi
from
Los Angeles, CA
Functionality of Male Condoms With a Silicone Elastomer Vaginal RIng
A Multicenter, Open-Label, Randomized, Two-Period, Crossover Non-inferiority Trial to Assess the Functionality of Male Condoms With a Silicone Elastomer Vaginal Ring
Status: Enrolling
Updated: 3/27/2018
California Family Health Council
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Functionality of Male Condoms With a Silicone Elastomer Vaginal RIng
A Multicenter, Open-Label, Randomized, Two-Period, Crossover Non-inferiority Trial to Assess the Functionality of Male Condoms With a Silicone Elastomer Vaginal Ring
Status: Enrolling
Updated:  3/27/2018
California Family Health Council, Inc.
mi
from
Berkeley, CA
Functionality of Male Condoms With a Silicone Elastomer Vaginal RIng
A Multicenter, Open-Label, Randomized, Two-Period, Crossover Non-inferiority Trial to Assess the Functionality of Male Condoms With a Silicone Elastomer Vaginal Ring
Status: Enrolling
Updated: 3/27/2018
California Family Health Council, Inc.
mi
from
Berkeley, CA
Click here to add this to my saved trials
Love, Sex & Choices: A Web Series on Mobile Devices to Reduce Black Women's HIV Risk
Reducing Urban Women's HIV Risk: Soap Opera Videos on Mobile Devices
Status: Enrolling
Updated:  3/27/2018
Northeastern University
mi
from
Boston, MA
Love, Sex & Choices: A Web Series on Mobile Devices to Reduce Black Women's HIV Risk
Reducing Urban Women's HIV Risk: Soap Opera Videos on Mobile Devices
Status: Enrolling
Updated: 3/27/2018
Northeastern University
mi
from
Boston, MA
Click here to add this to my saved trials